We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Nasal Vaccine Bolsters Immune Responses to COVID-19 in Vaccinated Animals

A doctor administers a nasal vaccine.
Credit: CDC/ Unsplash

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nasal Vaccine Bolsters Immune Responses to COVID-19 in Vaccinated Animals"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

A Yale-designed nasal vaccine can help bolster immune responses to COVID-19 in previously vaccinated animals and reduce viral transmission, Yale researchers report Oct. 27 in the journal Science.


The new vaccine approach developed by Yale researchers — which is known as “Prime and Spike” — is designed to jumpstart immune response in the respiratory system, which is the first part of the body to be infected by the virus.


Intramuscular vaccine shots, which are what most people have received to protect against COVID-19 infection, provide a broad-based immune response throughout the body and help avert serious illness. However, that protection has tended to wane after about four months, leaving people susceptible to breakthrough infections and emerging variants.


The new “prime” and “spike” approach may help prevent breakthrough infections of vaccinated individuals by bolstering immune response within the mucosal lining of the respiratory tract, which are the first cells attacked by COVID-19. (“Prime” refers to the process of injecting the vaccine directly into the muscle, as is typically done. “Spike” refers to a follow-up vaccination with spike proteins, known to derive from the coronavirus, directly into the nostril, where the virus is known to enter the body.)


The nasal vaccine promotes the development of immunity within the respiratory system, which can respond more quickly to infection,” said Dr. Benjamin Goldman-Israelow, assistant professor of medicine (infectious diseases) at the Yale School of Medicine and co-corresponding author of the paper. “By creating mucosal immunity, the vaccine helps stop the virus at its entry point, rather than waiting until later to fight back.”


The Yale team, led by Goldman-Israelow and Tianyang Mao, a graduate student in the lab of fellow co-corresponding author Aikiko Iwasaki, Sterling Professor of Immunobiology, delivered the nasal vaccine to both vaccinated and unvaccinated mice. They found increased immune system response in the respiratory tracks of vaccinated mice only. Mice that had not been previously vaccinated, and vaccinated mice that did not receive nasal vaccine, died from infection. Meanwhile, mice that received the intranasal spike booster were completely protected from death and disease.


In hamsters that received the nasal vaccine, the Yale team found decreased duration and total amount of viral shedding, which is when an infected individual releases copies of the virus including through sneezing or coughing. Hamsters vaccinated with the prime and spike method were also found to have reduced viral loads when housed in the same cage with infected, unvaccinated hamsters, suggesting that the strategy reduces trains of transmission.


Researchers also found increased breadth of immune response among animals that received the nasal vaccine, indicating that the approach would be effective against a broad spectrum of coronaviruses with pandemic potential.


Goldman-Israelow noted that the Yale approach does not use live viruses, viral vectors, or adjuvants, which may make the vaccine safer.


Reference: Mao T, Israelow B, Peña-Hernández MA, et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science. 2022:eabo2523. doi: 10.1126/science.abo2523


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement